News & Events

Learn about what's new with CMC Biologics

CMC Biologics Expands European GMP Manufacturing Capacity

News

Bioreactor 6Pack™ facility design provides innovative, flexible solutions to customers for phase III and commercial production

Seattle, WA and Berkeley, CA USA, and Copenhagen, Denmark – May 20, 2015CMC Biologics, Inc., Inc., a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its global manufacturing capacity expansion strategy, it will add approximately 14,000 liters of additional manufacturing capacity to its Copenhagen, Denmark facility.

CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe

News

Company plans to add more than 30,000L of bioreactor capacity across its three sites


Seattle, WA and Berkeley, CA USA, and Copenhagen, Denmark – May 7, 2015
CMC Biologics, Inc., a global leader in clinical and commercial manufacturing, announced today a plan to expand its global manufacturing capacity by more than 30,000 liters in the United States and Europe to meet growing customer demands for late-stage and commercial manufacturing.

CMC Biologics in Commercial Supply Agreement with Emergent BioSolutions for FDA-Approved IXINITY®

News

– Manufactured in CMC Biologics Seattle, Washington facility –


Seattle, WA – May 05, 2015
CMC Biologics, Inc., a global CMO dedicated to process development and production of biopharmaceuticals for clinical and commercial use, today announced that it will supply bulk drug substance for Emergent BioSolutions’ recently FDA-approved product, IXINITY® [coagulation factor IX (recombinant)]. IXINITY is a lyophilized powder for solution for intravenous injection. It is a coagulation factor IX (recombinant) indicated in adults and children ≥ 12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management. Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding.